01 May 2017
Karus Therapeutics presenting at the 18th Annual Drug Discovery Summit/5th Annual Discovery Chemistry & Drug Design
Oxford, UK, 1 May 2017 – Karus Therapeutics Ltd, a leader in the development of innovative medicines for the treatment of cancer, has announced its Chief Scientific Officer will be delivering a presentation at the 18th Annual Drug Discovery Summit/5th Annual Discovery Chemistry & Drug Design Congress, Berlin, 13 June 2017.
Stephen Shuttleworth, COO & CSO, will be presenting a presentation entitled Design & Development of KA2237: A Novel, Oral, Selective PI3K-p110β/δ Inhibitor for the Treatment of Cancer – Concept to Clinic.
For more information on Karus’s presentations or for media enquiries, please contact email@example.com.